Naseem Amin joined GMP-Orphan in 2016. He brings 26 years of trans-Atlantic industry experience in R and D, corporate development, business development, and marketing. Naseem most recently served as Chief Scientific Officer at Smith and Nephew, where he oversaw corporate R&D, divisional manufacturing, QA/QC and product development functions. Prior to Smith and Nephew, Naseem led business development at both Biogen Idec and at Genzyme Therapeutics, for both of which companies, he initiated and executed a number of transformative acquisitions and transactions.
He has also led the clinical development of five currently marketed therapeutic products. Naseem started his career at Baxter Healthcare where he had executive roles in marketing, product development and clinical research. In addition to his role at Advent, Naseem currently works as a board member and advisor to several not for profit organisations, and a publicly listed biotechnology company listed on the NASDAQ. Naseem is a qualified medical doctor, from the University College Medical School, London and has an MBA from Kellogg Graduate School of Management.